It’s nearly a year since the world discovered the age of Coronavirus. Now, 12 months later, we must consider the COVID-19 vaccine options in the United States.
On January 19, Pennsylvania, like other states, opened vaccine eligibility. To whom? To everyone over 65 or chronically ill, the highest priority group.
The unintended consequence is the pursuit of the vaccine. I hear people driving to other states to secure their first dose.
Consequently, it boils down to supply and demand. Pennsylvania received enough Moderna and Pfizer-BioNTech vaccines to protect 450,000 people last week. Pennsylvania has about 2.4 million people over 65 and older.
The Pennsylvania Vaccine Plan:
Phase One: First Responders
Essential Workers
People 65 & Older
Phase Two: High-Risk Population
Phase Three: Entire Population
What are the COVID-19 vaccine options in the United States? Let’s compare now that Johnson & Johnson-Janssen, the third vaccine, recently received emergency approval for use. As of March 1, the company had already shipped out 4 million doses.
The most significant difference between the third entry vaccine developed by Janssen is that it is a single-shot vaccine. It’s up to 85% effective in preventing the most serious coronavirus symptoms. And 66% effective at preventing moderate to severe illness.
I’m waiting to get the single-dose vaccine; I’m one of those who don’t like needles. My preference is one-and-done, with no concern about getting the second dose.
The single-dose vaccine could help boost the country’s vaccination rate. With all three vaccines, immunity builds over a few weeks after immunizations, regardless of the manufacturer.
It’s also worth noting that the J & J clinical trials took place later in the pandemic and in the regions where the variants emerged.
Please share if you secured your COVID-19 vaccine where you live.
As always, thank you for reading. Please continue to mask up and social distance even if you get your vaccine.
